Overview

A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis

Status:
Completed
Trial end date:
2017-03-14
Target enrollment:
Participant gender:
Summary
To assess safety, efficacy and pharmacokinetics of multiple dosesin patients with Bacterial Enteritis caused by Clostridium difficile infection(CDI) or Enteric infection.
Phase:
Phase 2
Details
Lead Sponsor:
Otsuka Pharmaceutical Co., Ltd.